LENZ Therapeutics (LENZ) Cash from Investing Activities (2022 - 2025)

LENZ Therapeutics (LENZ) has disclosed Cash from Investing Activities for 4 consecutive years, with -$89.8 million as the latest value for Q4 2025.

  • Quarterly Cash from Investing Activities fell 657.06% to -$89.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$75.7 million through Dec 2025, up 51.02% year-over-year, with the annual reading at -$75.7 million for FY2025, 51.02% up from the prior year.
  • Cash from Investing Activities for Q4 2025 was -$89.8 million at LENZ Therapeutics, down from -$4.3 million in the prior quarter.
  • The five-year high for Cash from Investing Activities was $18.9 million in Q1 2025, with the low at -$170.7 million in Q1 2022.
  • Average Cash from Investing Activities over 4 years is -$36.3 million, with a median of -$4.3 million recorded in 2025.
  • The sharpest move saw Cash from Investing Activities skyrocketed 300100.0% in 2024, then tumbled 657.06% in 2025.
  • Over 4 years, Cash from Investing Activities stood at $13.5 million in 2022, then plummeted by 100.04% to -$6000.0 in 2023, then crashed by 197616.67% to -$11.9 million in 2024, then crashed by 657.06% to -$89.8 million in 2025.
  • According to Business Quant data, Cash from Investing Activities over the past three periods came in at -$89.8 million, -$4.3 million, and -$414000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.